Your browser doesn't support javascript.
loading
Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
Martini, Alberto; Wever, Lieke; Soeterik, Timo F W; Rakauskas, Arnas; Fankhauser, Christian Daniel; Grogg, Josias Bastian; Checcucci, Enrico; Amparore, Daniele; Haiquel, Luciano; Rodriguez-Sanchez, Lara; Ploussard, Guillaume; Qiang, Peng; Affentranger, Andres; Marquis, Alessandro; Marra, Giancarlo; Ettala, Otto; Zattoni, Fabio; Falagario, Ugo Giovanni; De Angelis, Mario; Kesch, Claudia; Apfelbeck, Maria; Al-Hammouri, Tarek; Kretschmer, Alexander; Kasivisvanathan, Veeru; Preisser, Felix; Lefebvre, Emilie; Olivier, Jonathan; Radtke, Jan Philipp; Briganti, Alberto; Montorsi, Francesco; Carrieri, Giuseppe; Moro, Fabrizio Dal; Boström, Peter; Jambor, Ivan; Gontero, Paolo; Chiu, Peter K; John, Hubert; Macek, Petr; Porpiglia, Francesco; Hermanns, Thomas; van den Bergh, Roderick C N; van Basten, Jean-Paul A; Gandaglia, Giorgio; Valerio, Massimo.
Afiliación
  • Martini A; Department of Urology, La Croix du Sud Hospital, Toulouse, France.
  • Wever L; St Antonius Ziekenhuis, Nieuwegein, The Netherlands.
  • Soeterik TFW; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Rakauskas A; St Antonius Ziekenhuis, Nieuwegein, The Netherlands.
  • Fankhauser CD; Department of Urology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Grogg JB; Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Checcucci E; Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Amparore D; Department of Urology, San Luigi Hospital, Turin, Italy.
  • Haiquel L; Department of Urology, San Luigi Hospital, Turin, Italy.
  • Rodriguez-Sanchez L; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Ploussard G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Qiang P; Department of Urology, La Croix du Sud Hospital, Toulouse, France.
  • Affentranger A; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Marquis A; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Marra G; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • Ettala O; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • Zattoni F; Department of Urology, Turku University, Turku, Finland.
  • Falagario UG; Urology Unit, Academical Medical Centre Hospital, Udine, Italy.
  • De Angelis M; Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.
  • Kesch C; Department of Urology, University of Foggia, Foggia, Italy.
  • Apfelbeck M; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Al-Hammouri T; Department of Urology, University Hospital Essen, Essen, Germany.
  • Kretschmer A; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Kasivisvanathan V; Department of Urology, LMU, Munich, Germany.
  • Preisser F; Department of Urology, University College London and University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Lefebvre E; Department of Urology, LMU, Munich, Germany.
  • Olivier J; Department of Urology, University College London and University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Radtke JP; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.
  • Briganti A; Department of Urology, CHU Lille, Lille, France.
  • Montorsi F; Department of Urology, CHU Lille, Lille, France.
  • Carrieri G; Department of Urology, University Hospital Essen, Essen, Germany.
  • Moro FD; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Boström P; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Jambor I; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Gontero P; Department of Urology, University of Foggia, Foggia, Italy.
  • Chiu PK; Urology Unit, Academical Medical Centre Hospital, Udine, Italy.
  • John H; Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.
  • Macek P; Department of Urology, Turku University, Turku, Finland.
  • Porpiglia F; Department of Urology, Turku University, Turku, Finland.
  • Hermanns T; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • van den Bergh RCN; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
  • van Basten JA; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Gandaglia G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Valerio M; Department of Urology, San Luigi Hospital, Turin, Italy.
J Urol ; 210(1): 117-127, 2023 07.
Article en En | MEDLINE | ID: mdl-37052480
ABSTRACT

PURPOSE:

Bilateral extended pelvic lymph node dissection at the time of radical prostatectomy is the current standard of care if pelvic lymph node dissection is indicated; often, however, pelvic lymph node dissection is performed in pN0 disease. With the more accurate staging achieved with magnetic resonance imaging-targeted biopsies for prostate cancer diagnosis, the indication for bilateral extended pelvic lymph node dissection may be revised. We aimed to assess the feasibility of unilateral extended pelvic lymph node dissection in the era of modern prostate cancer imaging. MATERIALS AND

METHODS:

We analyzed a multi-institutional data set of men with cN0 disease diagnosed by magnetic resonance imaging-targeted biopsy who underwent prostatectomy and bilateral extended pelvic lymph node dissection. The outcome of the study was lymph node invasion contralateral to the prostatic lobe with worse disease features, ie, dominant lobe. Logistic regression to predict lymph node invasion contralateral to the dominant lobe was generated and internally validated.

RESULTS:

Overall, data from 2,253 patients were considered. Lymph node invasion was documented in 302 (13%) patients; 83 (4%) patients had lymph node invasion contralateral to the dominant prostatic lobe. A model including prostate-specific antigen, maximum diameter of the index lesion, seminal vesicle invasion on magnetic resonance imaging, International Society of Urological Pathology grade in the nondominant side, and percentage of positive cores in the nondominant side achieved an area under the curve of 84% after internal validation. With a cutoff of contralateral lymph node invasion of 1%, 602 (27%) contralateral pelvic lymph node dissections would be omitted with only 1 (1.2%) lymph node invasion missed.

CONCLUSIONS:

Pelvic lymph node dissection could be omitted contralateral to the prostate lobe with worse disease features in selected patients. We propose a model that can help avoid contralateral pelvic lymph node dissection in almost one-third of cases.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans / Male Idioma: En Revista: J Urol Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans / Male Idioma: En Revista: J Urol Año: 2023 Tipo del documento: Article País de afiliación: Francia
...